At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02257 SIRNAOMICS-B
Market Closed 09-27 16:08:28
3.420
+0.260
+8.23%
High3.580
Low3.000
Vol1.69M
Open3.200
D1 Closing3.160
Amplitude18.35%
Mkt Cap299.72M
Tradable Cap299.72M
Total Shares87.64M
T/O5.65M
T/O Rate1.92%
Tradable Shares87.64M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Sirnaomics Says Unit Signed Patent Assignment And License Agreement With Sagesse Bio
Sirnaomics Announces Completion of Ind-Enabling Studies of Safety and Efficacy for Stp125G With Nhp Models, Targeting Apoc3 for Treatment of Cardiovascular Diseases
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of Galnac-Based Rnai Therapeutic Stp122g for Anticoagulant Therapeutics
Sirnaomics Announces Completion of Stp707 Phase I Clinical Study With Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
Sirnaomics Ltd is a clinical-stage ribonucleic acid (RNA) therapeutics biopharmaceutical company. The Company is engaged in discovering and developing drugs for indications with unmet medical needs and market opportunities. The Company’s product pipeline has broad therapeutic utility across market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. The Company’s targets once selected based on clear scientific rationale, it applies an algorithm based on its understanding of the biochemical mechanisms involved in RNA interference to identify candidate RNA interference (RNAi) trigger sequences against the selected target gene and employ high throughput processes to design, screen and test future pipeline products. It has five ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in investigational new drug (IND) enabling or advanced preclinical studies.